Tebra vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
Practice management platform for 130K independent physicians from Kareo+PatientPop merger; EHR, billing, and patient acquisition marketing for small practices competing with athenahealth.
About
Tebra (formerly Kareo + PatientPop) is a cloud-based practice management and digital health platform for independent healthcare practices — providing practice management software, electronic health records (EHR), billing and revenue cycle management, patient engagement, and healthcare marketing tools specifically designed for small independent physician practices. Formed through the merger of Kareo (practice management/billing) and PatientPop (healthcare marketing/patient acquisition) in 2022, Tebra serves approximately 130,000 healthcare providers at independent practices across primary care, mental health, dermatology, and specialty care.\n\nTebra's platform addresses the full operational needs of a small medical practice: EHR documentation with templates for common visit types, automated patient appointment reminders and forms, insurance eligibility verification and claims submission, payment collection from patients, and online reputation management (Google reviews, healthcare directory listings). The combined Kareo+PatientPop heritage means Tebra uniquely covers both the clinical and administrative workflow alongside the digital marketing capabilities independent practices need to attract new patients.\n\nIn 2025, Tebra competes in the small practice EHR and practice management market against athenahealth, drchrono, Jane App, and Practice Fusion for independent physician practice software. The independent practice market faces significant headwinds from hospital consolidation — independent physician practices have steadily been acquired into health system employment or affiliated networks, shrinking the addressable market. Tebra's 2025 strategy focuses on the growing behavioral health segment (mental health practices are growing and need modern practice management tools), telehealth integration (virtual visit capability within the EHR workflow), and improving revenue cycle management automation to help practices collect more of what they bill.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.